CN107973830B - Total synthesis method of neooxytocin - Google Patents

Total synthesis method of neooxytocin Download PDF

Info

Publication number
CN107973830B
CN107973830B CN201711180837.9A CN201711180837A CN107973830B CN 107973830 B CN107973830 B CN 107973830B CN 201711180837 A CN201711180837 A CN 201711180837A CN 107973830 B CN107973830 B CN 107973830B
Authority
CN
China
Prior art keywords
compound
reaction
deoxy
benzoyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201711180837.9A
Other languages
Chinese (zh)
Other versions
CN107973830A (en
Inventor
邵华武
沈旭东
梁鹏
潘阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Institute of Biology of CAS
Original Assignee
Chengdu Institute of Biology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Institute of Biology of CAS filed Critical Chengdu Institute of Biology of CAS
Priority to CN201711180837.9A priority Critical patent/CN107973830B/en
Publication of CN107973830A publication Critical patent/CN107973830A/en
Application granted granted Critical
Publication of CN107973830B publication Critical patent/CN107973830B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)

Abstract

本发明属于药物化学和有机合成技术领域,目的是提供一种化学全合成新奥霉素的方法,具体包括:以D‑半乳糖等为原料,首先通过8步反应得到化合物14,随后与尿嘧啶缩合得到化合物15,再通过4步反应得到化合物19,接着与化合物6进行缩合得到化合物20,最后依次脱除酯保护基,再脱除Cbz保护基得到天然产物新奥霉素。本发明是首次合成天然产物新奥霉素的方法。本发明具有产物纯度高、成本低和操作简单等优点。The invention belongs to the technical field of medicinal chemistry and organic synthesis, and aims to provide a method for chemically synthesizing neo-Othomycin, which specifically includes: using D-galactose and the like as raw materials, firstly obtaining compound 14 through 8-step reactions, and then reacting with urine Pyrimidine is condensed to obtain compound 15, and then 4-step reaction is performed to obtain compound 19, which is then condensed with compound 6 to obtain compound 20. Finally, the ester protecting group is removed in turn, and then the Cbz protecting group is removed to obtain the natural product neoorthomycin. The present invention is the first method for synthesizing natural product neoorthomycin. The invention has the advantages of high product purity, low cost, simple operation and the like.

Description

一种新奥霉素的全合成方法A kind of total synthesis method of neoorthomycin

技术领域technical field

本发明属于药物化学和有机合成技术领域,具体涉及新奥霉素的化学合成方法。The invention belongs to the technical field of medicinal chemistry and organic synthesis, and in particular relates to a chemical synthesis method of neo-Othomycin.

背景技术Background technique

作为新型的农药,生物农药因其绿色环保和安全高效等特点在近几十年得到了快速的发展(Trends in Biotechnology 2012,30,250-258;Phil. Trans.R.Soc.B2011,366,1987-1998;Biosystems Engineering 2003,84, 119-125等)。其中,核苷类抗生素因其广泛的生物活性已引起了化学合成工作者的极大兴趣(J.Antibiot.1988,41,1711-1739;Pharm.Therap. 1991,52,269-286;Nat.Prod.Rep.2010,27,279-304;Trends inMicrobiology 2015,23,110-119等)。许多文献报道了一些核苷类抗生素在农作物保护方面良好的应用前景(Chem.Rev.1992,92,1745-1768; Chem.Rev.1995,95,1859-1876;Heterocycles2005,65,667-695;Pest Manag.Sci.2007,63,524-554等)。As a new type of pesticide, biopesticides have developed rapidly in recent decades due to their green environmental protection, safety and high efficiency (Trends in Biotechnology 2012, 30, 250-258; Phil. Trans.R.Soc.B2011,366,1987- 1998; Biosystems Engineering 2003, 84, 119-125 et al). Among them, nucleoside antibiotics have attracted great interest in chemical synthesis workers because of their wide range of biological activities (J. Antibiot. 1988, 41, 1711-1739; Pharm. Therap. 1991, 52, 269-286; Nat. Prod. Rep. 2010, 27, 279-304; Trends in Microbiology 2015, 23, 110-119, etc.). Many literatures have reported that some nucleoside antibiotics have good application prospects in crop protection (Chem. Rev. 1992, 92, 1745-1768; Chem. Rev. 1995, 95, 1859-1876; .Sci.2007, 63, 524-554, etc.).

新奥霉素(Xinaomycin)是一种多肽核苷类农用抗生素,由诺尔斯氏链霉菌xinao-4的发酵液中分离而得(CN200910060121)。作为广谱的核苷类农用抗生素,新奥霉素具有抗细菌、抗真菌和抗病毒活性。田间药效试验表明,4%的新奥霉素水剂对于防治烟草花叶病毒病具有很好的效果,且明显高于市售对照药剂20%吗胍·乙酸铜可湿性粉剂(Mod.Agrochem.2011,10,50-52);对番茄花叶病毒病有较好的防治效果,且对番茄生长安全(J.Henan Agric.Sci.2013,42,86-88);对水稻白叶枯病、青枯病和软腐病等细菌病害也具有防治效果。此外,新奥霉素表现出对油菜菌核病菌和小麦纹枯病菌较强的抑制活性,其抑菌效果与多抗霉素相当(Agrochemicals 2013,52,293-294)。Xinaomycin is a polypeptide nucleoside agricultural antibiotic, which is isolated from the fermentation broth of Streptomyces knowlesii xinao-4 (CN200910060121). As a broad-spectrum nucleoside agricultural antibiotic, neoorthomycin has antibacterial, antifungal and antiviral activities. The field efficacy test showed that 4% neo-octomycin water has a good effect on the prevention and control of tobacco mosaic virus disease, and it is significantly higher than the commercial control agent 20% morphine·copper acetate wettable powder (Mod. Agrochem .2011, 10, 50-52); has a good control effect on tomato mosaic virus disease, and is safe for tomato growth (J. Henan Agric. Sci. 2013, 42, 86-88); Bacterial diseases such as bacterial wilt, bacterial wilt and soft rot also have control effects. In addition, neoorthomycin showed strong inhibitory activity against Sclerotinia sclerotiorum and Rhizoctonia solani, and its bacteriostatic effect was comparable to that of polyantimycin (Agrochemicals 2013, 52, 293-294).

然而,通过微生物发酵所得的新奥霉素产率较低。为了提高新奥霉素的产率,一些关于新奥霉素生物合成基因簇的研究已经展开。虽然在诺尔斯氏链霉菌xinao-4基因操控系统的研究中取得了一些进展,但是生物合成新奥霉素产率低的问题仍然没有解决(Int.J.Mol.Sci.2014,15, 12217-12230)。此外,由于新奥霉素的极性大,发酵液中含有大量氨基酸和糖类物质,成分复杂,同系物多,导致分离纯化有一定难度。因此,如何大量地获取纯度较高的新奥霉素就显得十分有意义。However, the yield of neoorthomycin obtained by microbial fermentation is low. In order to improve the yield of neo-octomycin, some studies on the biosynthetic gene cluster of neo-octomycin have been carried out. Although some progress has been made in the study of the xinao-4 gene manipulation system of Streptomyces knowlesii, the problem of the low yield of biosynthetic neoorthomycin remains unsolved (Int.J.Mol.Sci.2014, 15, 12217 -12230). In addition, due to the high polarity of neoorthomycin, the fermentation broth contains a large amount of amino acids and carbohydrates, the composition is complex, and there are many homologs, which lead to certain difficulties in separation and purification. Therefore, it is very meaningful to obtain a large amount of high-purity neo-octomycin.

化学全合成是获取大量的高纯度的天然产物的重要技术思路。但目前还没有新奥霉素全合成的报道。Total chemical synthesis is an important technical idea to obtain a large number of high-purity natural products. However, there is no report on the total synthesis of neoorthomycin.

发明内容SUMMARY OF THE INVENTION

本发明的目的是提供一种化学全合成新奥霉素的方法,即是以D- 半乳糖等为原料,通过一系列反应实现了新奥霉素的化学全合成。The purpose of the present invention is to provide a method for the total chemical synthesis of neo-Othomycin, that is, using D-galactose and the like as raw materials, through a series of reactions, the total chemical synthesis of neo-Othomycin is realized.

为实现上述发明目的,本发明合成了一种新的化学物质:化合物18,并利用化合物18进一步反应,合成新奥霉素。In order to achieve the above purpose of the invention, the present invention has synthesized a new chemical substance: compound 18, and further reacted with compound 18 to synthesize neoorthomycin.

化合物18,名称为:2’,3’-二-O-苯甲酰基-4’-叠氮基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷,化学结构式为:Compound 18, named: 2',3'-di-O-benzoyl-4'-azido-4'-deoxy-α-D-glucuronide methyl uridine, the chemical structure is:

Figure BDA0001479137150000021
Figure BDA0001479137150000021

相应的,所述化合物18的制备方法,具体包括如下步骤:Correspondingly, the preparation method of compound 18 specifically includes the following steps:

1)、将2’,3’-二-O-苯甲酰基-4’-叠氮基-4’-去氧-α-D-葡萄糖尿苷,简称为:化合物16,与TEMPO一起加入CH3CN中,再加入醋酸碘苯,并反应完全,而后加入无水EtOH进行淬灭反应,浓缩得固体粗品,命名为:化合物17;1), add 2',3'-di-O-benzoyl-4'-azido-4'-deoxy-α-D-glucouridine, referred to as: compound 16, and add CH together with TEMPO 3 CN, then add iodobenzene acetate, and the reaction is complete, then add anhydrous EtOH to quench the reaction, concentrate to obtain a solid crude product, named: compound 17;

2)、所述化合物17溶于无水CH3OH,加入H2SO4,反应完全,再加入NaHCO3进行淬灭反应,浓缩;用乙酸乙酯萃取反应液,再干燥、过滤、减压浓缩,得化合物18。2), the compound 17 was dissolved in anhydrous CH 3 OH, added H 2 SO 4 , the reaction was complete, then NaHCO 3 was added to quench the reaction, and concentrated; the reaction solution was extracted with ethyl acetate, then dried, filtered, and decompressed. Concentration gave compound 18.

优选的,所述的化合物18的制备方法中,所述化合物14的合成方法为:Preferably, in the preparation method of compound 18, the synthesis method of compound 14 is:

1)、将化合物14与尿嘧啶在TMSOTf/BSA/乙腈条件下回流反应得到化合物15,化合物15在Et3N/CH3OH中水解得到化合物16;所述化合物14与15的命名分别为:化合物14:1,6-二-O-乙酰基-2,3-二-O-苯甲酰基-4-叠氮基-4-去氧-α-D-葡萄糖;化合物15:2’,3’-二-O-苯甲酰基-4’- 叠氮基-6’-O-乙酰基-4’-去氧-α-D-葡萄糖尿苷;1), the backflow reaction of compound 14 and uracil under TMSOTf/BSA/acetonitrile conditions obtains compound 15, and compound 15 is hydrolyzed in Et 3 N/CH 3 OH to obtain compound 16; the names of the compounds 14 and 15 are respectively: Compound 14: 1,6-Di-O-acetyl-2,3-di-O-benzoyl-4-azido-4-deoxy-α-D-glucose; Compound 15: 2',3 '-Di-O-benzoyl-4'-azido-6'-O-acetyl-4'-deoxy-α-D-glucouridine;

2)、所述化合物14的合成方法为:2), the synthetic method of described compound 14 is:

将化合物13在H2SO4/AcOH/Ac2O条件下反应得到化合物14;所述化合物13的命名为:2,3-二-O-苯甲酰基-4-叠氮基-6-O-叔丁基二甲基硅基-4-去氧-α-D-葡萄糖甲苷;Compound 13 was reacted under the condition of H 2 SO 4 /AcOH/Ac 2 O to obtain compound 14; the name of compound 13 was: 2,3-di-O-benzoyl-4-azido-6-O - tert-butyldimethylsilyl-4-deoxy-α-D-glucoside methyloside;

3)、所述化合物13的合成方法为:化合物11在CH3ONa/CH3OH 中水解并随后在DMF中加入咪唑和TBSCl反应得到化合物12,化合物 12在吡啶中与BzCl反应得到化合物13;所述化合物11与12的命名分别为:化合物11:4-叠氮基-2,3,6-三-O-苯甲酰基-4-去氧-α-D-葡萄糖甲苷,化合物12:4-叠氮基-6-O-叔丁基二甲基硅基-4-去氧-α-D-葡萄糖甲苷。3) The synthesis method of the compound 13 is as follows: the compound 11 is hydrolyzed in CH 3 ONa/CH 3 OH, and then imidazole and TBSCl are added to the DMF to react to obtain the compound 12, and the compound 12 is reacted with BzCl in the pyridine to obtain the compound 13; The names of the compounds 11 and 12 are respectively: compound 11: 4-azido-2,3,6-tri-O-benzoyl-4-deoxy-α-D-glucoside, compound 12: 4-Azido-6-O-tert-butyldimethylsilyl-4-deoxy-α-D-glucoside methyloside.

进一步的,利用化合物18合成的化合物19,名称为:2’,3’-二-O- 苯甲酰基-4’-氨基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷,化学结构式为:Further, compound 19 synthesized by compound 18 is named: 2',3'-di-O-benzoyl-4'-amino-4'-deoxy-α-D-glucuronate methyl uridine , the chemical structure is:

Figure BDA0001479137150000031
Figure BDA0001479137150000031

相应的,所述的化合物19的制备方法为:将所述化合物18与 SnCl2·H2O、对甲基苯硫酚、CHCl3和Et3N反应,分离获得化合物19。Correspondingly, the preparation method of the compound 19 is as follows: the compound 18 is reacted with SnCl 2 ·H 2 O, p-methylthiophenol, CHCl 3 and Et 3 N, and the compound 19 is obtained by isolation.

进一步的,利用化合物19合成的化合物20,名称为:(R)-2’,3’-二-O- 苯甲酰基-4’-(2”-(2”’-(N-甲基,N-Cbz)氨基)乙酰氨基-3”-羟基)丙酰胺基 -4’-去氧-α-D-葡萄糖醛酸甲酯尿苷,化学结构式为:Further, compound 20 synthesized by compound 19 is named: (R)-2',3'-di-O-benzoyl-4'-(2"-(2"'-(N-methyl, N-Cbz) amino) acetamido-3 "-hydroxyl) propionamido-4'-deoxy-α-D-glucuronide methyl uridine, the chemical structural formula is:

Figure BDA0001479137150000041
Figure BDA0001479137150000041

相应的,所述的化合物20的制备方法为:以所述化合物19、 (R)-2-[2’-(N-甲基,N-Cbz)氨基]乙酰氨基-3-羟基丙酸为原料,以HATU为缩合剂,以2,6-二甲基吡啶为碱,充分反应,经萃取、洗涤、干燥、过滤和浓缩后,分离获得化合物20。Correspondingly, the preparation method of the compound 20 is as follows: using the compound 19, (R)-2-[2'-(N-methyl, N-Cbz)amino]acetamido-3-hydroxypropionic acid as The raw materials were fully reacted with HATU as a condensing agent and 2,6-lutidine as a base, and after extraction, washing, drying, filtration and concentration, compound 20 was isolated and obtained.

进一步的,利用化合物20合成的化合物21,名称为: (R)-4’-(2”-(2”’-(N-甲基,N-Cbz)氨基)乙酰氨基-3”-羟基)丙酰胺基-4’-去氧-α-D-葡萄糖醛酸尿苷,化学结构式为:Further, compound 21 synthesized by compound 20 is named: (R)-4'-(2"-(2"'-(N-methyl,N-Cbz)amino)acetamido-3"-hydroxyl) Propionamido-4'-deoxy-α-D-glucuronide uridine, the chemical structure is:

Figure BDA0001479137150000042
Figure BDA0001479137150000042

相应的,所述的化合物21的制备方法为:将所述化合物20于0℃下在LiOH的甲醇水溶液中水解,浓缩并进行HPLC制备,得到化合物 21。Correspondingly, the preparation method of the compound 21 is as follows: the compound 20 is hydrolyzed in LiOH aqueous methanol solution at 0°C, concentrated and prepared by HPLC to obtain the compound 21.

进一步的,利用所述化合物21合成新奥霉素的全合成方法为:将所述化合物21和含量为10%的Pd/C加入到EtOH和水中,在氢气的条件下室温反应完全,过滤和浓缩得到新奥霉素。Further, the total synthesis method of using the compound 21 to synthesize neoorthomycin is as follows: the compound 21 and Pd/C with a content of 10% are added to EtOH and water, the reaction is completed at room temperature under the condition of hydrogen, and the mixture is filtered and purified. Concentration yields neo-Othomycin.

相应的,本发明所获得和利用到的全合成新奥霉素的中间体,都是新颖的具有独立的使用和保护价值,请求专利保护。Correspondingly, the intermediates of the total synthesis of neo-Othomycin obtained and utilized in the present invention are novel and have independent use and protection value, and patent protection is requested.

本发明的有益效果:Beneficial effects of the present invention:

1、本发明是首次合成天然产物新奥霉素的方法,真正实现了其人工全合成;1, the present invention is the method for synthesizing natural product neoorthomycin for the first time, and truly realizes its artificial total synthesis;

2、本发明以廉价易得的D-半乳糖等为起始原料,具有成本低、操作简单、产物纯度极高的特点;2. The present invention uses cheap and easy-to-obtain D-galactose and the like as starting materials, and has the characteristics of low cost, simple operation and extremely high product purity;

3、本发明的合成路线,可以在新奥霉素化学结构的多个位置同时进行多种修饰,为新奥霉素结构类似物的合成和开发新的高效低毒的生物农药奠定了基础。3. The synthetic route of the present invention can simultaneously carry out various modifications at multiple positions of the chemical structure of neo-Othomycin, which lays a foundation for the synthesis of neo-Othomycin structural analogs and the development of new high-efficiency and low-toxic biological pesticides.

附图说明Description of drawings

图1为新奥霉素全合成路线图;Fig. 1 is the total synthesis route map of neo-Othomycin;

图2为化合物18:2’,3’-二-O-苯甲酰基-4’-叠氮基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷的核磁共振氢谱图;Figure 2 shows the hydrogen NMR spectrum of compound 18: 2',3'-di-O-benzoyl-4'-azido-4'-deoxy-α-D-glucuronide methyl uridine ;

图3为化合物18:2’,3’-二-O-苯甲酰基-4’-叠氮基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷的核磁共振碳谱图;Figure 3 is the carbon NMR spectrum of compound 18: 2',3'-di-O-benzoyl-4'-azido-4'-deoxy-α-D-glucuronide methyl uridine ;

图4为化合物19:2’,3’-二-O-苯甲酰基-4’-氨基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷的核磁共振氢谱图;Fig. 4 is compound 19: 2',3'-di-O-benzoyl-4'-amino-4'-deoxy-α-D-glucuronic acid methyl uridine hydrogen NMR spectrum;

图5为化合物19:2’,3’-二-O-苯甲酰基-4’-氨基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷的核磁共振碳谱图;Figure 5 is the carbon nuclear magnetic resonance spectrum of compound 19: 2',3'-di-O-benzoyl-4'-amino-4'-deoxy-α-D-glucuronate methyl uridine;

图6为化合物20:(R)-2’,3’-二-O-苯甲酰基-4’-(2”-(2”’-(N-甲基,N-Cbz)氨基)乙酰氨基-3”-羟基)丙酰胺基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷的核磁共振氢谱图;Figure 6 is compound 20: (R)-2',3'-di-O-benzoyl-4'-(2"-(2"'-(N-methyl,N-Cbz)amino)acetamido -3"-Hydroxy)propionamido-4'-deoxy-α-D-glucuronide methyl uridine 1H NMR spectrum;

图7为化合物20:(R)-2’,3’-二-O-苯甲酰基-4’-(2”-(2”’-(N-甲基,N-Cbz)氨基)乙酰氨基-3”-羟基)丙酰胺基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷的核磁共振碳谱图;Figure 7 is compound 20: (R)-2',3'-di-O-benzoyl-4'-(2"-(2"'-(N-methyl,N-Cbz)amino)acetamido -3"-Hydroxy)propionamido-4'-deoxy-α-D-glucuronide methyl uridine carbon NMR spectrum;

图8为化合物21:(R)-4’-(2”-(2”’-(N-甲基,N-Cbz)氨基)乙酰氨基-3”- 羟基)丙酰胺基-4’-去氧-α-D-葡萄糖醛酸尿苷的核磁共振氢谱图;Figure 8 is compound 21: (R)-4'-(2"-(2"'-(N-methyl,N-Cbz)amino)acetamido-3"-hydroxy)propionamido-4'-de 1H NMR spectrum of oxygen-α-D-glucuronide uridine;

图9为化合物21:(R)-4’-(2”-(2”’-(N-甲基,N-Cbz)氨基)乙酰氨基-3”- 羟基)丙酰胺基-4’-去氧-α-D-葡萄糖醛酸尿苷的核磁共振碳谱图;Figure 9 is compound 21: (R)-4'-(2"-(2"'-(N-methyl,N-Cbz)amino)acetamido-3"-hydroxy)propionamido-4'-de Carbon NMR spectrum of oxygen-α-D-glucuronide uridine;

图10为化合物22:(R)-4’-(2”-(2”’-(N-甲基)氨基)乙酰氨基-3”-羟基) 丙酰胺基-4’-去氧-α-D-葡萄糖醛酸尿苷(新奥霉素)的核磁共振氢谱图;Figure 10 is compound 22: (R)-4'-(2"-(2"'-(N-methyl)amino)acetamido-3"-hydroxy)propionamido-4'-deoxy-α- 1H NMR spectrum of uridine D-glucuronide (neoorthomycin);

图11为化合物22:(R)-4’-(2”-(2”’-(N-甲基)氨基)乙酰氨基-3”-羟基) 丙酰胺基-4’-去氧-α-D-葡萄糖醛酸尿苷(新奥霉素)的核磁共振碳谱图;Figure 11 is compound 22: (R)-4'-(2"-(2"'-(N-methyl)amino)acetamido-3"-hydroxy)propionamido-4'-deoxy-α- C NMR spectrum of uridine D-glucuronide (neoorthomycin);

图12为天然产物新奥霉素:(R)-4’-(2”-(2”’-(N-甲基)氨基)乙酰氨基 -3”-羟基)丙酰胺基-4’-去氧-α-D-葡萄糖醛酸尿苷(天然产物新奥霉素) 的核磁共振氢谱图;Figure 12 is the natural product neo-octomycin: (R)-4'-(2"-(2"'-(N-methyl)amino)acetamido-3"-hydroxy)propionamido-4'-de 1H NMR spectrum of oxo-α-D-glucuronide uridine (natural product neo-Othomycin);

图13为天然产物新奥霉素:(R)-4’-(2”-(2”’-(N-甲基)氨基)乙酰氨基 -3”-羟基)丙酰胺基-4’-去氧-α-D-葡萄糖醛酸尿苷(天然产物新奥霉素) 的核磁共振碳谱图。Figure 13 is the natural product neo-octomycin: (R)-4'-(2"-(2"'-(N-methyl)amino)acetamido-3"-hydroxy)propionamido-4'-de Carbon NMR spectrum of oxo-α-D-glucuronide uridine (a natural product neo-othomycin).

具体实施方式Detailed ways

因本发明涉及系列化学反应,为使本领域技术人员能够理解本发明的技术方案,故提供一例详细实施例。本领域技术人员应当明确,在本实施例基础上,适当调整合成原料、工艺方法和参数以达到相同目的,都在本发明保护范围内。Since the present invention involves a series of chemical reactions, a detailed example is provided to enable those skilled in the art to understand the technical solutions of the present invention. It should be clear to those skilled in the art that, on the basis of the present embodiment, appropriate adjustment of synthetic raw materials, process methods and parameters to achieve the same purpose are all within the protection scope of the present invention.

1、合成:D-丝氨酸甲酯盐酸盐(化合物2)1. Synthesis: D-serine methyl ester hydrochloride (compound 2)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000061
Figure BDA0001479137150000061

因本发明涉及大量化合物及化学反应方程式,为更方便地进行说明和阐述,全文对合成步骤中的重要中间产物全部进行标号处理,标号方式为:化合物+数字,如本例所示,将D-丝氨酸甲酯盐酸盐简称为:化合物2;并在化学反应方程式中的化学结构式下方注明对应序号,如本例所示,在D-丝氨酸甲酯盐酸盐的结构式下方标明:2。Because the present invention involves a large number of compounds and chemical reaction equations, for the sake of more convenient description and elaboration, all important intermediate products in the synthesis steps are all labeled in the full text, and the labeling method is: compound + number, as shown in this example, D -Serine methyl ester hydrochloride is abbreviated as: compound 2; and the corresponding serial number is indicated below the chemical structural formula in the chemical reaction equation. As shown in this example, it is indicated below the structural formula of D-serine methyl ester hydrochloride: 2.

将二氯亚砜(18.68g,157.00mmol)在N2保护下缓慢滴加到冰盐浴冷却的无水CH3OH(30mL)中,滴加完以后,将反应液升至室温搅拌半小时。然后加入如上述反应方程式所述的化合物1(5.00g,47.58mmol),室温下反应12小时,反应液由浑浊变澄清。浓缩反应液,并真空干燥后得白色固体:化合物2(7.10g,96%)。Thionyl chloride (18.68 g, 157.00 mmol) was slowly added dropwise to anhydrous CH 3 OH (30 mL) cooled in an ice-salt bath under the protection of N 2 . After the dropwise addition, the reaction solution was warmed to room temperature and stirred for half an hour . Then, compound 1 (5.00 g, 47.58 mmol) as described in the above reaction formula was added, and the reaction was carried out at room temperature for 12 hours, and the reaction solution became clear from turbidity. The reaction solution was concentrated and dried in vacuo to obtain a white solid: compound 2 (7.10 g, 96%).

化合物2属于现有原料,也可以直接采购。Compound 2 is an existing raw material and can also be purchased directly.

2、合成:2-(N-甲基,N-Cbz)氨基乙酸(化合物4)2. Synthesis: 2-(N-methyl, N-Cbz)aminoacetic acid (compound 4)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000071
Figure BDA0001479137150000071

将化合物3肌氨酸(3.00g,33.67mmol)加入到NaOH(3.24g,80.90 mmol)的水溶液中(100mL),冰水浴下搅拌成均相。滴加CbzCl(6.89g, 40.39mmol)。室温下搅拌16小时后,TLC监测原料反应完全。用乙酸乙酯洗涤反应液(2×100mL),水层用1M盐酸洗涤至pH为2,随后用乙酸乙酯萃取(2×150mL)。合并的乙酸乙酯溶液用饱和NaCl溶液(100 mL)洗涤,无水Na2SO4干燥,过滤,减压浓缩,得无色油状物N-Cbz- 肌氨酸:化合物4(7.11g,94%)。Compound 3 sarcosine (3.00 g, 33.67 mmol) was added to an aqueous solution of NaOH (3.24 g, 80.90 mmol) (100 mL), and the mixture was stirred under an ice-water bath to form a homogeneous phase. CbzCl (6.89 g, 40.39 mmol) was added dropwise. After stirring at room temperature for 16 hours, the starting material was monitored by TLC for completion. The reaction solution was washed with ethyl acetate (2 x 100 mL), the aqueous layer was washed with 1 M hydrochloric acid to pH 2, then extracted with ethyl acetate (2 x 150 mL). The combined ethyl acetate solution was washed with saturated NaCl solution (100 mL), dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure to give a colorless oil N-Cbz-sarcosine: compound 4 (7.11 g, 94 %).

3、合成:(R)-2-[2’-(N-甲基,N-Cbz)氨基]乙酰氨基-3-羟基丙酸甲酯 (化合物5)3. Synthesis: (R)-2-[2'-(N-methyl, N-Cbz)amino]acetamido-3-hydroxypropionic acid methyl ester (Compound 5)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000072
Figure BDA0001479137150000072

将化合物4(6.00g,26.88mmol)溶于干燥DMF(80mL)中,随后依次加入HATU(18.33g,48.21mmol)和2,6-二甲基吡啶(10.14g,94.62 mmol),并于室温下搅拌2小时。加入上述化合物2(5.80g,37.30mmol),室温下继续搅拌14小时后,TLC监测原料反应完全。加入饱和NaCl 溶液(250mL),用乙酸乙酯萃取反应液(3×200mL)。合并的乙酸乙酯溶液用饱和NaCl溶液(2×200mL)洗涤,无水Na2SO4干燥,过滤,减压浓缩。所得浓缩物经硅胶柱层析分离(CH2Cl2/MeOH,50:1),得无色油状物:化合物5(6.45g,74%)。Compound 4 (6.00 g, 26.88 mmol) was dissolved in dry DMF (80 mL), followed by the addition of HATU (18.33 g, 48.21 mmol) and 2,6-lutidine (10.14 g, 94.62 mmol), and the mixture was heated to room temperature under stirring for 2 hours. The above compound 2 (5.80 g, 37.30 mmol) was added, and after stirring at room temperature for 14 hours, TLC monitored the reaction of the starting materials to complete. Saturated NaCl solution (250 mL) was added, and the reaction solution was extracted with ethyl acetate (3×200 mL). The combined ethyl acetate solution was washed with saturated NaCl solution (2 x 200 mL), dried over anhydrous Na2SO4 , filtered and concentrated under reduced pressure. The obtained concentrate was separated by silica gel column chromatography (CH 2 Cl 2 /MeOH, 50:1) to give a colorless oil: compound 5 (6.45 g, 74%).

4、合成:(R)-2-[2’-(N-甲基,N-Cbz)氨基]乙酰氨基-3-羟基丙酸(化合物6)4. Synthesis: (R)-2-[2'-(N-methyl, N-Cbz)amino]acetamido-3-hydroxypropionic acid (compound 6)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000081
Figure BDA0001479137150000081

将化合物5(3.80g,11.72mmol)溶于CH3OH(30mL)中,0℃下滴加 LiOH·H2O(639.3mg,15.24mmol)的水溶液(10mL)。搅拌1小时后, TLC监测原料反应完全。滴加1M盐酸调溶液至pH=1。加水(100mL),用乙酸乙酯萃取(2×150mL)。合并的乙酸乙酯溶液用饱和NaCl溶液 (100mL)洗涤,无水Na2SO4干燥,过滤,减压浓缩,得白色固体:化合物6(2.76g,76%)。Compound 5 (3.80 g, 11.72 mmol) was dissolved in CH 3 OH (30 mL), and an aqueous solution (10 mL) of LiOH·H 2 O (639.3 mg, 15.24 mmol) was added dropwise at 0°C. After stirring for 1 hour, TLC monitored the completion of the starting material. 1M hydrochloric acid was added dropwise to adjust the solution to pH=1. Water (100 mL) was added and extracted with ethyl acetate (2 x 150 mL). The combined ethyl acetate solution was washed with saturated NaCl solution (100 mL), dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure to give a white solid: compound 6 (2.76 g, 76%).

5、合成:4-羟基-2,3,6-三-O-苯甲酰基-α-D-半乳糖甲苷(化合物9)5. Synthesis: 4-hydroxy-2,3,6-tri-O-benzoyl-α-D-galactoside (compound 9)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000082
Figure BDA0001479137150000082

将乙酰氯(7.5mL)滴加至冰水浴冷却的无水甲醇(350mL)中,滴加完以后,将反应液升至室温搅拌半小时。然后加入如上述反应方程式所述的化合物7:D-半乳糖(25.00g,0.14mol),氮气保护下加热回流12 小时,反应液由浑浊变为澄清。将反应液冷却至室温,加入固体NaHCO3,调至pH=8。过滤,浓缩滤液,用油泵抽干溶剂,得到粗产物:化合物8(34.3g),并直接进行下一步反应。将化合物8(34.3g)溶于吡啶(300mL) 中,–20℃下冷却。滴加BzCl(68.39g,0.49mol),并缓慢升至室温搅拌 18小时。滴加甲醇(50mL)淬灭反应。浓缩,加水(800mL),用乙酸乙酯萃取反应液(3×500mL)。合并的乙酸乙酯溶液用1M盐酸洗涤至 pH=2,再用饱和NaCl溶液(2×400mL)洗涤,无水Na2SO4干燥,过滤,减压浓缩。所得浓缩物经硅胶柱层析分离(石油醚/乙酸乙酯,8:1),得无色油状物:化合物9:4-羟基-2,3,6-三-O-苯甲酰基-α-D-半乳糖甲苷 (35.90g,51%,twosteps)。1H NMR(400MHz,CDCl3)δ8.10–7.97(m,6H), 7.64–7.37(m,9H),5.78(dd,J=10.7,2.9Hz,1H),5.72(dd,J=10.7,3.5 Hz,1H),5.24(d,J=3.4Hz,1H),4.70(dd,J=11.4,5.8Hz,1H),4.59(dd,J =11.4,6.9Hz,1H),4.43(d,J=1.6Hz,1H),4.38(t,J=6.3Hz,1H),3.47(s, 3H),2.84–2.50(br,1H);13C NMR(100MHz,CDCl3)δ166.5,166.1,165.8, 133.5,133.3,129.9,129.8,129.7,129.6,129.3,128.5,128.4,97.5,70.8, 68.9,68.2,67.7,63.4,55.5。Acetyl chloride (7.5 mL) was added dropwise to anhydrous methanol (350 mL) cooled in an ice-water bath. After the dropwise addition, the reaction solution was warmed to room temperature and stirred for half an hour. Then, compound 7: D-galactose (25.00 g, 0.14 mol) as described in the above reaction equation was added, and the mixture was heated to reflux for 12 hours under nitrogen protection, and the reaction solution changed from turbid to clear. The reaction solution was cooled to room temperature, and solid NaHCO 3 was added to adjust pH=8. Filter, concentrate the filtrate, and dry the solvent with an oil pump to obtain a crude product: compound 8 (34.3 g), which is directly subjected to the next reaction. Compound 8 (34.3 g) was dissolved in pyridine (300 mL) and cooled at -20°C. BzCl (68.39 g, 0.49 mol) was added dropwise, and the mixture was slowly warmed to room temperature and stirred for 18 hours. The reaction was quenched by dropwise addition of methanol (50 mL). Concentrate, add water (800 mL), and extract the reaction solution with ethyl acetate (3×500 mL). The combined ethyl acetate solution was washed with 1M hydrochloric acid to pH=2, then with saturated NaCl solution (2 x 400 mL), dried over anhydrous Na2SO4 , filtered and concentrated under reduced pressure. The obtained concentrate was separated by silica gel column chromatography (petroleum ether/ethyl acetate, 8:1) to obtain a colorless oily substance: compound 9: 4-hydroxy-2,3,6-tri-O-benzoyl-α - D-galactoside (35.90 g, 51%, two steps). 1 H NMR (400MHz, CDCl 3 ) δ 8.10-7.97 (m, 6H), 7.64-7.37 (m, 9H), 5.78 (dd, J=10.7, 2.9Hz, 1H), 5.72 (dd, J=10.7 ,3.5 Hz,1H),5.24(d,J=3.4Hz,1H),4.70(dd,J=11.4,5.8Hz,1H),4.59(dd,J=11.4,6.9Hz,1H),4.43(d , J=1.6Hz, 1H), 4.38(t, J=6.3Hz, 1H), 3.47(s, 3H), 2.84–2.50(br, 1H); 13 C NMR(100MHz, CDCl 3 )δ166.5,166.1, 165.8, 133.5, 133.3, 129.9, 129.8, 129.7, 129.6, 129.3, 128.5, 128.4, 97.5, 70.8, 68.9, 68.2, 67.7, 63.4, 55.5.

6、合成:4-叠氮基-2,3,6-三-O-苯甲酰基-4-去氧-α-D-葡萄糖甲苷(化合物11)6. Synthesis: 4-azido-2,3,6-tri-O-benzoyl-4-deoxy-α-D-glucoside (compound 11)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000091
Figure BDA0001479137150000091

将化合物9(10.00g,19.74mmol)和吡啶(6.25g,78.96mmol)溶于 CH2Cl2(100mL)中,–10℃下滴加Tf2O(5.57g,19.74mmol)。–10℃下反应1.5小时后,TLC监测原料反应完全。反应液用1M盐酸洗涤至 pH=2,再用水(2×100mL)洗涤,无水Na2SO4干燥,过滤,减压浓缩,所得粗品:化合物10,直接进行下一步反应。将化合物粗品溶于DMF(80 mL)中,加入NaN3(2.57g,39.48mmol)。室温下反应16小时后,TLC 监测原料反应完全。向反应液中加入饱和NaCl溶液(300mL),用乙酸乙酯萃取(3×200mL)。合并的乙酸乙酯溶液用饱和NaCl溶液(2×200 mL)洗涤,无水Na2SO4干燥。过滤,减压浓缩。所得浓缩物经硅胶柱层析分离(石油醚/乙酸乙酯,12:1),得无色油状物:化合物11:4-叠氮基 -2,3,6-三-O-苯甲酰基-4-去氧-α-D-葡萄糖甲苷(7.87g,75%,twosteps)。1H NMR(600MHz,CDCl3)δ8.11(d,J=7.4Hz,2H),8.00(d,J=7.4Hz,2H), 7.97(d,J=7.4Hz,2H),7.61(t,J=7.4Hz,1H),7.54–7.48(m,4H),7.38(q, J=7.5Hz,4H),6.00(t,J=9.9Hz,1H),5.20(dd,J=10.0,3.6Hz,1H), 5.17(d,J=3.6Hz,1H),4.71(dd,J=12.1,2.1Hz,1H),4.63(dd,J=12.1, 4.7Hz,1H),4.09–4.03(m,1H),3.86(t,J=10.1Hz,1H),3.44(s,3H);13C NMR(100MHz,CDCl3)δ166.2,160.0,165.6,133.5,133.4,130.0,129.9, 129.8,129.6,129.1,128.9,128.6,128.5,97.2,71.9,71.0,68.0,63.4,61.0, 55.7.Compound 9 (10.00 g, 19.74 mmol) and pyridine (6.25 g, 78.96 mmol) were dissolved in CH 2 Cl 2 (100 mL), and Tf 2 O (5.57 g, 19.74 mmol) was added dropwise at -10°C. After 1.5 hours of reaction at -10°C, the reaction of the starting material was monitored by TLC for completion. The reaction solution was washed with 1M hydrochloric acid to pH=2, then washed with water (2×100 mL), dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure to obtain crude product: compound 10, which was directly carried out to the next reaction. The crude compound was dissolved in DMF (80 mL) and NaN3 ( 2.57 g, 39.48 mmol) was added. After 16 hours at room temperature, TLC monitored the starting material for completion. Saturated NaCl solution (300 mL) was added to the reaction solution, followed by extraction with ethyl acetate (3×200 mL). The combined ethyl acetate solution was washed with saturated NaCl solution (2 x 200 mL) and dried over anhydrous Na2SO4 . Filter and concentrate under reduced pressure. The obtained concentrate was separated by silica gel column chromatography (petroleum ether/ethyl acetate, 12:1) to obtain a colorless oil: compound 11: 4-azido-2,3,6-tri-O-benzoyl - 4-Deoxy-α-D-glucoside tetrakis (7.87 g, 75%, two steps). 1 H NMR (600 MHz, CDCl 3 ) δ 8.11 (d, J=7.4 Hz, 2H), 8.00 (d, J=7.4 Hz, 2H), 7.97 (d, J=7.4 Hz, 2H), 7.61 (t , J=7.4Hz, 1H), 7.54–7.48(m, 4H), 7.38(q, J=7.5Hz, 4H), 6.00(t, J=9.9Hz, 1H), 5.20(dd, J=10.0, 3.6Hz, 1H), 5.17(d, J=3.6Hz, 1H), 4.71(dd, J=12.1, 2.1Hz, 1H), 4.63(dd, J=12.1, 4.7Hz, 1H), 4.09–4.03( m, 1H), 3.86 (t, J=10.1 Hz, 1H), 3.44 (s, 3H); 13 C NMR (100 MHz, CDCl 3 ) δ 166.2, 160.0, 165.6, 133.5, 133.4, 130.0, 129.9, 129.8, 129.6 ,129.1,128.9,128.6,128.5,97.2,71.9,71.0,68.0,63.4,61.0,55.7.

7、合成:4-叠氮基-6-O-叔丁基二甲基硅基-4-去氧-α-D-葡萄糖甲苷 (化合物12)7. Synthesis: 4-azido-6-O-tert-butyldimethylsilyl-4-deoxy-α-D-glucoside (Compound 12)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000101
Figure BDA0001479137150000101

将化合物11(20.00g,37.63mmol)溶于CH3OH(100mL)中,加入 CH3ONa(0.61g,11.29mmol)。室温下反应15小时后,TLC监测反应完全。浓缩,并抽真空至恒重,得粗品。将粗品溶于DMF(80mL)中,加入咪唑(7.69g,11mmol),并于0℃下分批加入TBSCl(8.51g,56.44mmol)。缓慢升至室温反应16小时后,TLC监测反应完全。向反应液中加入饱和NaCl溶液(300mL),用乙酸乙酯萃取(4×200mL)。合并的乙酸乙酯溶液用饱和NaCl溶液(2×200mL)洗涤,无水Na2SO4干燥,过滤,减压浓缩。所得浓缩物经硅胶柱层析分离(石油醚/乙酸乙酯, 5:1-1:1),得无色油状物:化合物12(7.90g,63%)。1H NMR(400MHz, CDCl3)δ4.79(d,J=3.8Hz,1H),3.84(d,J=1.0Hz,2H),3.81(t,J=9.3 Hz,1H),3.55(dd,J=9.5,3.8Hz,1H),3.51–3.46(m,2H),3.41(s,3H), 3.33–3.10(br,2H),0.93(s,9H),0.10(s,6H);13CNMR(100MHz,CDCl3)δ 99.2,73.4,72.5,70.8,62.5,61.5,55.3,25.9,18.4,-5.3,-5.4.Compound 11 (20.00 g, 37.63 mmol) was dissolved in CH3OH (100 mL ) and CH3ONa (0.61 g, 11.29 mmol) was added. After 15 hours at room temperature, the reaction was completed by TLC monitoring. Concentrated and evacuated to constant weight to obtain crude product. The crude product was dissolved in DMF (80 mL), imidazole (7.69 g, 11 mmol) was added, and TBSCl (8.51 g, 56.44 mmol) was added portionwise at 0 °C. After slowly warming to room temperature for 16 hours, the reaction was monitored by TLC for completion. Saturated NaCl solution (300 mL) was added to the reaction solution, followed by extraction with ethyl acetate (4×200 mL). The combined ethyl acetate solution was washed with saturated NaCl solution (2 x 200 mL), dried over anhydrous Na2SO4 , filtered and concentrated under reduced pressure. The obtained concentrate was separated by silica gel column chromatography (petroleum ether/ethyl acetate, 5:1-1:1) to obtain a colorless oil: compound 12 (7.90 g, 63%). 1 H NMR(400MHz, CDCl 3 )δ4.79(d,J=3.8Hz,1H),3.84(d,J=1.0Hz,2H),3.81(t,J=9.3Hz,1H),3.55(dd , J=9.5, 3.8Hz, 1H), 3.51–3.46 (m, 2H), 3.41 (s, 3H), 3.33–3.10 (br, 2H), 0.93 (s, 9H), 0.10 (s, 6H); 13 CNMR (100MHz, CDCl 3 ) δ 99.2, 73.4, 72.5, 70.8, 62.5, 61.5, 55.3, 25.9, 18.4, -5.3, -5.4.

8、合成:2,3-二-O-苯甲酰基-4-叠氮基-6-O-叔丁基二甲基硅基-4-去氧-α-D-葡萄糖甲苷(化合物13)8. Synthesis: 2,3-di-O-benzoyl-4-azido-6-O-tert-butyldimethylsilyl-4-deoxy-α-D-glucoside (Compound 13 )

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000111
Figure BDA0001479137150000111

将化合物12(7.50g,22.49mmol)溶于吡啶(80mL)中,0℃下滴加BzCl(7.59g,53.98mmol)。室温反应16小时后,TLC监测反应完全。滴加甲醇(10mL)淬灭反应。浓缩,加水(200mL),用二氯甲烷萃取反应液(3×200mL)。合并的二氯甲烷溶液用1M盐酸洗涤至pH=2,饱和NaCl溶液(2×200mL)洗涤,无水Na2SO4干燥,过滤,减压浓缩。所得浓缩物经硅胶柱层析分离(石油醚/乙酸乙酯,20:1),得无色油状物:化合物13(11.01g,90%)。1HNMR(400MHz,CDCl3)δ8.09–7.96 (m,4H),7.57–7.48(m,2H),7.44–7.36(m,4H),5.96(dd,J=15.6,5.6Hz, 1H),5.20–5.14(m,2H),4.01–3.90(m,3H),3.76(dd,J=10.2,1.5Hz,1H), 3.42(s,3H),1.00(s,9H),0.18(s,3H),0.17(s,3H);13CNMR(100MHz, CDCl3)δ166.0,165.7,133.4,133.3,130.0,129.9,129.8,129.3,129.1,128.4, 97.1,72.1,71.1,70.4,62.2,60.3,55.4,26.0,18.5,-5.2,-5.4.Compound 12 (7.50 g, 22.49 mmol) was dissolved in pyridine (80 mL), and BzCl (7.59 g, 53.98 mmol) was added dropwise at 0°C. After 16 hours at room temperature, the reaction was completed by TLC monitoring. The reaction was quenched by dropwise addition of methanol (10 mL). Concentrate, add water (200 mL), and extract the reaction solution with dichloromethane (3 x 200 mL). The combined dichloromethane solution was washed with 1M hydrochloric acid to pH=2, saturated NaCl solution (2 x 200 mL), dried over anhydrous Na2SO4 , filtered and concentrated under reduced pressure. The obtained concentrate was separated by silica gel column chromatography (petroleum ether/ethyl acetate, 20:1) to obtain a colorless oil: compound 13 (11.01 g, 90%). 1 H NMR (400MHz, CDCl 3 ) δ 8.09-7.96 (m, 4H), 7.57-7.48 (m, 2H), 7.44-7.36 (m, 4H), 5.96 (dd, J=15.6, 5.6Hz, 1H) ,5.20–5.14(m,2H),4.01–3.90(m,3H),3.76(dd,J=10.2,1.5Hz,1H), 3.42(s,3H),1.00(s,9H),0.18(s , 3H), 0.17(s, 3H); 13 CNMR (100MHz, CDCl 3 ) δ 166.0, 165.7, 133.4, 133.3, 130.0, 129.9, 129.8, 129.3, 129.1, 128.4, 97.1, 72.1, 71.1, 70.4, 62.2, 60.3 ,55.4,26.0,18.5,-5.2,-5.4.

9、合成:1,6-二-O-乙酰基-2,3-二-O-苯甲酰基-4-叠氮基-4-去氧-α-D- 葡萄糖(化合物14)9. Synthesis: 1,6-di-O-acetyl-2,3-di-O-benzoyl-4-azido-4-deoxy-α-D-glucose (compound 14)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000112
Figure BDA0001479137150000112

将化合物13(10.00g,18.46mmol)加入AcOH(33mL)和Ac2O(67 mL)中,0℃下滴加H2SO4(2.0mL)。在0℃下反应2天后,TLC监测反应完全。将反应液倾入冰水(400mL)中,用二氯甲烷萃取(3×200 mL)。合并的二氯甲烷溶液用水(2×400mL)洗涤,饱和NaHCO3溶液洗涤至pH=8,饱和NaCl溶液(2×300mL)洗涤,无水Na2SO4干燥,过滤,减压浓缩。所得浓缩物经硅胶柱层析分离(石油醚/乙酸乙酯,3:1),得白色固体:化合物14(5.41g,59%)。1HNMR(400MHz,CDCl3)δ8.03 (d,J=7.6Hz,2H),7.92(d,J=7.5Hz,2H),7.60–7.49(m,2H),7.46–7.36 (m,4H),6.54(d,J=3.6Hz,1H),5.96(t,J=10.0Hz,1H),5.42(dd,J= 10.2,3.6Hz,1H),4.48–4.36(m,2H),4.05(d,J=10.3Hz,1H),3.94(t,J= 10.2Hz,1H),2.20(s,6H);13CNMR(100MHz,CDCl3)δ170.5,168.6, 165.6,165.4,133.7,133.6,129.8,128.7,128.5,89.3,70.8,70.4,70.1,62.5, 60.3,20.8.Compound 13 (10.00 g, 18.46 mmol) was added to AcOH (33 mL) and Ac 2 O (67 mL), and H 2 SO 4 (2.0 mL) was added dropwise at 0°C. After 2 days of reaction at 0°C, the completion of the reaction was monitored by TLC. The reaction solution was poured into ice water (400 mL) and extracted with dichloromethane (3×200 mL). The combined dichloromethane solution was washed with water (2 x 400 mL), saturated NaHCO 3 solution to pH=8, saturated NaCl solution (2 x 300 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The obtained concentrate was separated by silica gel column chromatography (petroleum ether/ethyl acetate, 3:1) to obtain a white solid: compound 14 (5.41 g, 59%). 1 HNMR (400MHz, CDCl 3 ) δ 8.03 (d, J=7.6Hz, 2H), 7.92 (d, J=7.5Hz, 2H), 7.60-7.49 (m, 2H), 7.46-7.36 (m, 4H) ),6.54(d,J=3.6Hz,1H),5.96(t,J=10.0Hz,1H),5.42(dd,J=10.2,3.6Hz,1H),4.48–4.36(m,2H),4.05 (d, J=10.3Hz, 1H), 3.94 (t, J=10.2Hz, 1H), 2.20 (s, 6H); 13 CNMR (100MHz, CDCl 3 ) δ 170.5, 168.6, 165.6, 165.4, 133.7, 133.6, 129.8, 128.7, 128.5, 89.3, 70.8, 70.4, 70.1, 62.5, 60.3, 20.8.

10、合成:2’,3’-二-O-苯甲酰基-4’-叠氮基-6’-O-乙酰基-4’-去氧-α-D- 葡萄糖尿苷(化合物15)10. Synthesis: 2',3'-di-O-benzoyl-4'-azido-6'-O-acetyl-4'-deoxy-α-D-glucouridine (compound 15)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000121
Figure BDA0001479137150000121

将尿嘧啶(1.38g,12.33mmol)、BSA(7.53g,37.00mmol)加入到 CH3CN(40mL)中,室温下搅拌10分钟,反应液由浑浊变为澄清。加入化合物14(4.09g,8.22mmol),随后加入TMSOTf(12.79g,57.55 mmol)。N2保护下加热回流16小时后,TLC监测反应完全。浓缩,加水(200mL),用乙酸乙酯萃取反应液(3×200mL)。合并的乙酸乙酯溶液用饱和NaCl溶液(2×200mL)洗涤,无水Na2SO4干燥,过滤,减压浓缩。所得粗品经CH3OH重结晶,得淡黄色固体:化合物15(3.58g, 79%)。1HNMR(400MHz,DMSO-d6)δ11.37(s,1H),7.92(d,J=8.1Hz, 3H),7.77(d,J=7.3Hz,2H),7.71–7.58(m,2H),7.55–7.42(m,4H),6.33(d, J=9.1Hz,1H),6.05(t,J=9.5Hz,1H),5.80–5.69(m,2H),4.41(d,J= 11.8Hz,1H),4.34–4.28(m,1H),4.26–4.13(m,2H),2.11(s,3H).Uracil (1.38 g, 12.33 mmol) and BSA (7.53 g, 37.00 mmol) were added to CH 3 CN (40 mL), and stirred at room temperature for 10 minutes, the reaction solution turned from turbid to clear. Compound 14 (4.09 g, 8.22 mmol) was added followed by TMSOTf (12.79 g, 57.55 mmol). After heating at reflux under N2 for 16 h, the reaction was complete as monitored by TLC. Concentrate, add water (200 mL), and extract the reaction solution with ethyl acetate (3 x 200 mL). The combined ethyl acetate solution was washed with saturated NaCl solution (2 x 200 mL), dried over anhydrous Na2SO4 , filtered and concentrated under reduced pressure. The resulting crude product was recrystallized from CH3OH to give a pale yellow solid: compound 15 (3.58 g, 79%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.37 (s, 1H), 7.92 (d, J=8.1 Hz, 3H), 7.77 (d, J=7.3 Hz, 2H), 7.71-7.58 (m, 2H) ), 7.55–7.42 (m, 4H), 6.33 (d, J=9.1Hz, 1H), 6.05 (t, J=9.5Hz, 1H), 5.80–5.69 (m, 2H), 4.41 (d, J= 11.8Hz, 1H), 4.34–4.28 (m, 1H), 4.26–4.13 (m, 2H), 2.11 (s, 3H).

11、合成:2’,3’-二-O-苯甲酰基-4’-叠氮基-4’-去氧-α-D-葡萄糖尿苷 (化合物16)11. Synthesis: 2',3'-di-O-benzoyl-4'-azido-4'-deoxy-α-D-glucouridine (Compound 16)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000131
Figure BDA0001479137150000131

将化合物15(3.14g,5.71mmol)溶于无水CH3OH(200mL)中,加入 Et3N(4.04g,40.00mmol)。室温反应48小时后,反应液由浑浊变为澄清, TLC监测反应完全。在40℃下浓缩反应液,得固体粗品。用乙醚洗涤,得淡黄色固体:化合物16(2.47g,85%)。Compound 15 (3.14 g, 5.71 mmol) was dissolved in anhydrous CH3OH (200 mL) and Et3N ( 4.04 g, 40.00 mmol) was added. After 48 hours of reaction at room temperature, the reaction solution turned from turbid to clear, and TLC monitored the reaction to complete. The reaction solution was concentrated at 40°C to obtain a solid crude product. Washed with ether to give pale yellow solid: compound 16 (2.47 g, 85%).

12、合成:2’,3’-二-O-苯甲酰基-4’-叠氮基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷(化合物18)12. Synthesis: 2',3'-di-O-benzoyl-4'-azido-4'-deoxy-α-D-glucuronide methyl uridine (compound 18)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000132
Figure BDA0001479137150000132

将化合物16(1.20g,2.37mmol)、TEMPO(73.9mg,0.47mmol)加入到 CH3CN(15mL)和水(12mL)中。分批加入醋酸碘苯(1.90g,5.91 mmol),室温下搅拌6小时后,TLC监测反应完全。加入无水EtOH(5mL) 淬灭反应,浓缩。所得粗品:化合物17,直接进行下一步反应。将上述粗品溶于无水CH3OH(20mL)中,加入H2SO4(0.4mL)。加热回流4小时后,TLC监测反应完全。加入NaHCO3淬灭反应,浓缩。加水(40mL),用乙酸乙酯萃取反应液(3×40mL)。合并的乙酸乙酯溶液用饱和NaCl 溶液(2×50mL)洗涤,无水Na2SO4干燥,过滤,减压浓缩。所得浓缩物经硅胶柱层析分离(石油醚/乙酸乙酯,1:1),得白色固体:化合物18 (558.1mg,44%,twosteps)。1H NMR(400MHz,CDCl3)δ8.27(s,1H), 7.97(d,J=7.2Hz,2H),7.87(d,J=7.2Hz,2H),7.60–7.46(m,3H), 7.45–7.34(m,4H),6.15(d,J=9.5Hz,1H),5.90–5.74(m,2H),5.57(t,J= 9.5Hz,1H),4.30–4.13(m,2H),3.92(s,3H,OCH3).13C NMR(101MHz,CDCl3)δ166.86,165.27,165.24,162.66,162.63,150.17,139.21,134.00, 133.84,130.19,130.01,129.87,128.59,128.44,128.34,127.62,103.88, 80.71,77.26,75.84,72.80,69.50,61.40,53.51.ESI-HRMS:m/zcalcdfor C25H22N5O9[M+H]+:536.1412;found:536.1419.Compound 16 (1.20 g, 2.37 mmol), TEMPO (73.9 mg, 0.47 mmol) were added to CH3CN (15 mL) and water (12 mL). Iodobenzene acetate (1.90 g, 5.91 mmol) was added in portions, and after stirring at room temperature for 6 hours, TLC monitored the reaction to complete. The reaction was quenched by the addition of anhydrous EtOH (5 mL) and concentrated. The obtained crude product: compound 17, directly proceed to the next reaction. The above crude product was dissolved in anhydrous CH3OH ( 20 mL ) and H2SO4 (0.4 mL) was added. After heating at reflux for 4 hours, TLC monitored the reaction for completion. The reaction was quenched by the addition of NaHCO3 and concentrated. Water (40 mL) was added, and the reaction solution was extracted with ethyl acetate (3×40 mL). The combined ethyl acetate solution was washed with saturated NaCl solution (2 x 50 mL), dried over anhydrous Na2SO4 , filtered and concentrated under reduced pressure. The obtained concentrate was separated by silica gel column chromatography (petroleum ether/ethyl acetate, 1:1) to obtain a white solid: compound 18 (558.1 mg, 44%, two steps). 1 H NMR (400 MHz, CDCl 3 ) δ 8.27 (s, 1H), 7.97 (d, J=7.2 Hz, 2H), 7.87 (d, J=7.2 Hz, 2H), 7.60-7.46 (m, 3H) , 7.45–7.34 (m, 4H), 6.15 (d, J=9.5Hz, 1H), 5.90–5.74 (m, 2H), 5.57 (t, J= 9.5Hz, 1H), 4.30–4.13 (m, 2H) The _ _ , 127.62, 103.88, 80.71, 77.26, 75.84, 72.80, 69.50, 61.40, 53.51. ESI-HRMS: m/zcalcd for C 25 H 22 N 5 O 9 [M+H] + :536.1412; found: 536.1419.

13、合成:2’,3’-二-O-苯甲酰基-4’-氨基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷(化合物19)13. Synthesis: 2',3'-di-O-benzoyl-4'-amino-4'-deoxy-α-D-glucuronate methyl uridine (compound 19)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000141
Figure BDA0001479137150000141

将SnCl2·H2O(295.0mg,1.31mmol)、对甲基苯硫酚(324.9mg,2.62 mmol)加入到CHCl3(5mL)中,室温下滴加Et3N(396.3mg,3.92mmol)。搅拌5分钟,加入化合物18(350.0mg,0.65mmol)。室温反应2小时后, TLC监测反应完全。加硅胶拌样,经硅胶柱层析分离(CH2Cl2/CH3OH, 40:1),得白色固体:化合物19(288.1mg,86%)。1H NMR(400MHz, DMSO-d6)δ11.39(s,1H),7.99(d,J=8.1Hz,1H),7.90(d,J=7.3Hz,2H), 7.75(d,J=7.3Hz,2H),7.61(t,J=7.4Hz,2H),7.46(q,J=8.0Hz,4H), 6.17(d,J=8.3Hz,1H),5.78–5.62(m,3H),4.50(d,J=10.1Hz,1H),3.73 (s,3H),1.93–1.61(br,2H,NH2).13CNMR(101MHz,DMSO)δ168.71,165.95,165.03,163.09,150.81,141.46,134.37,133.94,129.74,129.55, 129.31,129.10,128.70,103.14,78.56,76.12,71.36,53.70,52.75,29.48. ESI-HRMS:m/zcalcdforC25H23N3O9[M+H]+:509.1434;found: 510.1514.SnCl 2 ·H 2 O (295.0 mg, 1.31 mmol), p-methylthiophenol (324.9 mg, 2.62 mmol) were added to CHCl 3 (5 mL), and Et 3 N (396.3 mg, 3.92 mmol) was added dropwise at room temperature ). After stirring for 5 minutes, compound 18 (350.0 mg, 0.65 mmol) was added. After 2 hours at room temperature, TLC monitored the completion of the reaction. Silica gel was added to the mixture, and the mixture was separated by silica gel column chromatography (CH 2 Cl 2 /CH 3 OH, 40:1) to obtain a white solid: compound 19 (288.1 mg, 86%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.39 (s, 1H), 7.99 (d, J=8.1 Hz, 1H), 7.90 (d, J=7.3 Hz, 2H), 7.75 (d, J= 7.3Hz, 2H), 7.61 (t, J=7.4Hz, 2H), 7.46 (q, J=8.0Hz, 4H), 6.17 (d, J=8.3Hz, 1H), 5.78–5.62 (m, 3H) , 4.50 (d, J=10.1Hz, 1H), 3.73 (s, 3H), 1.93–1.61 (br, 2H, NH 2 ). 13 CNMR (101MHz, DMSO) δ 168.71, 165.95, 165.03, 163.09, 150.81, 141.46 ,134.37,133.94,129.74,129.55, 129.31,129.10,128.70,103.14,78.56,76.12,71.36,53.70,52.75,29.48. ESI-HRMS:m/zcalcdforC 25 H 23 N 3 O 9 :M + H] 509.1434; found: 510.1514.

14、合成:(R)-2’,3’-二-O-苯甲酰基-4’-(2”-(2”’-(N-甲基,N-Cbz)氨基)乙酰氨基-3”-羟基)丙酰胺基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷(化合物20)14. Synthesis: (R)-2',3'-di-O-benzoyl-4'-(2"-(2"'-(N-methyl,N-Cbz)amino)acetamido-3 "-Hydroxy)propionamido-4'-deoxy-α-D-glucuronide methyl uridine (Compound 20)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000151
Figure BDA0001479137150000151

将上述化合物6(200mg,0.65mmol)溶于干燥DMF(5mL)中,随后依次加入HATU(490.0mg,1.29mmol)和2,6-二甲基吡啶(172.5mg, 1.61mmol),并于室温下搅拌2小时。再加入化合物19(164.1mg,0.32 mmol),室温下继续搅拌14小时后,TLC监测原料反应完全。加入饱和 NaCl溶液(30mL),用乙酸乙酯萃取反应液(3×30mL)。合并的乙酸乙酯溶液用饱和NaCl溶液(2×30mL)洗涤,无水Na2SO4干燥,过滤,减压浓缩。所得浓缩物经硅胶柱层析分离(CH2Cl2/CH3OH,50:1),得白色固体:化合物20(178.0mg,69%)。1HNMR(400MHz,DMSO-d6)δ11.40(s,1H),8.24(t,J=7.4Hz,1H),8.15(d,J=8.1Hz,1H),8.03(d,J= 7.9Hz,1H),7.77(d,J=7.3Hz,4H),7.66–7.57(m,2H),7.50–7.41(m,4H), 7.39–7.26(m,5H),6.21(d,J=8.5Hz,1H),5.89–5.77(m,2H),5.74(d,J= 8.1Hz,1H),5.08(s,1H),5.02(dd,J=21.3,8.4Hz,1H),4.73–4.61(m,3H), 4.33–4.22(m,1H),3.99–3.80(m,2H),3.57(d,J=16.9Hz,3H,O-CH3), 3.31–3.15(m,2H),2.84(d,J=16.4Hz,3H,N-CH3).13CNMR(150MHz, D2O)δ170.72,168.49,167.54,165.75,164.93,163.10,156.42,156.11, 150.81,141.64,137.41,134.42,129.65,129.62,129.48,129.33,129.05, 128.87,128.66,128.26,127.85,127.57,103.16,75.24,73.27,71.26,66.73, 60.29,52.86,51.42,51.07,50.27,29.46,27.01.ESI-HRMS:m/zcalcdfor C39H40N5O14[M+H]+:802.2513;found:802.2586.The above compound 6 (200 mg, 0.65 mmol) was dissolved in dry DMF (5 mL), followed by the addition of HATU (490.0 mg, 1.29 mmol) and 2,6-lutidine (172.5 mg, 1.61 mmol) in sequence, and the mixture was heated to room temperature. under stirring for 2 hours. Compound 19 (164.1 mg, 0.32 mmol) was added, and after stirring at room temperature for 14 hours, the reaction of the starting materials was monitored by TLC for completeness. Saturated NaCl solution (30 mL) was added, and the reaction solution was extracted with ethyl acetate (3×30 mL). The combined ethyl acetate solution was washed with saturated NaCl solution (2 x 30 mL), dried over anhydrous Na2SO4 , filtered and concentrated under reduced pressure. The obtained concentrate was separated by silica gel column chromatography (CH 2 Cl 2 /CH 3 OH, 50:1) to obtain a white solid: compound 20 (178.0 mg, 69%). 1 HNMR (400MHz, DMSO-d 6 ) δ 11.40 (s, 1H), 8.24 (t, J=7.4Hz, 1H), 8.15 (d, J=8.1Hz, 1H), 8.03 (d, J=7.9 Hz, 1H), 7.77(d, J=7.3Hz, 4H), 7.66–7.57 (m, 2H), 7.50–7.41 (m, 4H), 7.39–7.26 (m, 5H), 6.21 (d, J= 8.5Hz, 1H), 5.89–5.77 (m, 2H), 5.74 (d, J=8.1Hz, 1H), 5.08 (s, 1H), 5.02 (dd, J=21.3, 8.4Hz, 1H), 4.73– 4.61(m, 3H), 4.33-4.22(m, 1H), 3.99-3.80(m, 2H), 3.57(d, J=16.9Hz, 3H, O-CH 3 ), 3.31-3.15(m, 2H) , 2.84 (d, J=16.4Hz, 3H, N-CH 3 ). 13 CNMR (150MHz, D 2 O) δ 170.72, 168.49, 167.54, 165.75, 164.93, 163.10, 156.42, 156.11, 150.81, 141.64, 137.421, 134. ,129.65,129.62,129.48,129.33,129.05, 128.87,128.66,128.26,127.85,127.57,103.16,75.24,73.27,71.26,66.73, 60.29,52.86,51.42,51.07,50.27,29.46,27.01.ESI-HRMS:m / zcalcdfor C39H40N5O14 [M+H] + : 802.2513 ;found: 802.2586 .

15、合成:(R)-4’-(2”-(2”’-(N-甲基,N-Cbz)氨基)乙酰氨基-3”-羟基) 丙酰胺基-4’-去氧-α-D-葡萄糖醛酸尿苷(化合物21)15. Synthesis: (R)-4'-(2"-(2"'-(N-methyl,N-Cbz)amino)acetamido-3"-hydroxy)propionamido-4'-deoxy- α-D-uridine glucuronide (compound 21)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000161
Figure BDA0001479137150000161

将化合物20(200mg,0.25mmol)溶于CH3OH(5mL)中,0℃下滴加 LiOH·H2O(41.9mg,1.00mmol)的水溶液(3mL)。在0℃下搅拌3小时后,TLC监测原料反应完全。滴加AcOH调溶液pH=2。浓缩反应液并进行HPLC制备,得到白色固体:化合物21(43.3mg,30%)。1H NMR(400MHz,D2O)δ7.74(d,J=7.2Hz,1H),7.40–7.16(m,5H),5.80(d,J=7.6 Hz,1H),5.56–5.42(m,1H),5.17–4.90(m,2H),4.32(d,J=34.1Hz,1H), 4.02–3.87(m,2H),3.85–3.74(m,2H),3.72–3.52(m,3H),2.95–2.74(m, 3H).13CNMR(150MHz,D2O)δ171.70,171.66,165.81,158.32,157.83, 151.85,141.81,136.14,128.78,128.41,127.72,103.15,82.33,73.51,71.22, 67.89,61.48,55.55,53.08,51.59,35.94.ESI-HRMS:m/z calcd for C24H30N5O12[M+H]+:580.1813;found:580.1885.Compound 20 (200 mg, 0.25 mmol) was dissolved in CH 3 OH (5 mL), and an aqueous solution (3 mL) of LiOH·H 2 O (41.9 mg, 1.00 mmol) was added dropwise at 0°C. After stirring at 0°C for 3 hours, the starting material was monitored by TLC for completion. AcOH was added dropwise to adjust the pH of the solution to 2. The reaction solution was concentrated and subjected to HPLC preparation to obtain a white solid: compound 21 (43.3 mg, 30%). 1 H NMR (400MHz, D 2 O) δ 7.74 (d, J=7.2 Hz, 1H), 7.40-7.16 (m, 5H), 5.80 (d, J=7.6 Hz, 1H), 5.56-5.42 (m ,1H),5.17–4.90(m,2H),4.32(d,J=34.1Hz,1H), 4.02–3.87(m,2H),3.85–3.74(m,2H),3.72–3.52(m,3H a _ 67.89, 61.48, 55.55, 53.08, 51.59, 35.94. ESI-HRMS: m/z calcd for C 24 H 30 N 5 O 12 [M+H] + : 580.1813; found: 580.1885.

16、合成:(R)-4’-(2”-(2”’-(N-甲基)氨基)乙酰氨基-3”-羟基)丙酰胺基-4’-去氧-α-D-葡萄糖醛酸尿苷(新奥霉素)16. Synthesis: (R)-4'-(2"-(2"'-(N-methyl)amino)acetamido-3"-hydroxy)propionamido-4'-deoxy-α-D- Uridine glucuronide (neoorthomycin)

化学反应方程式为:The chemical reaction equation is:

Figure BDA0001479137150000162
Figure BDA0001479137150000162

将化合物21(25.0mg,0.0431mmol)、含量为10%的Pd/C(10.0mg)加入到EtOH(3mL)和水(3mL)中,在氢气的条件下室温反应15分钟后,TLC监测反应完全。过滤,浓缩,得白色固体:化合物22,即目标产物新奥霉素(19.2mg,100%)。[α]20 D+37.0(c0.74,H2O);1HNMR(600MHz, D2O)δ7.81(d,J=7.9Hz,1H),5.89(d,J=7.9Hz,1H),5.57(s,1H),4.48 (t,J=5.3Hz,1H),3.96(s,2H),3.83–3.77(m,3H),3.76–3.70(m,2H),2.64 (s,3H);13CNMR(150MHz,D2O)δ174.0,171.4,168.1,166.4,152.3, 142.0,103.1,82.4,77.9,73.6,71.6,61.4,55.7,53.4,50.2,33.2;ESI-HRMS: m/zcalcdforC16H23N5NaO10[M+Na]+:468.1337;found:468.1324。Compound 21 (25.0 mg, 0.0431 mmol) and 10% Pd/C (10.0 mg) were added to EtOH (3 mL) and water (3 mL), and reacted at room temperature for 15 minutes under the presence of hydrogen, and the reaction was monitored by TLC completely. Filtration and concentration to obtain a white solid: compound 22, the target product neoorthomycin (19.2 mg, 100%). [α] 20 D +37.0 (c0.74, H 2 O); 1 HNMR (600 MHz, D 2 O) δ 7.81 (d, J=7.9 Hz, 1H), 5.89 (d, J=7.9 Hz, 1H) ), 5.57(s, 1H), 4.48 (t, J=5.3Hz, 1H), 3.96(s, 2H), 3.83–3.77(m, 3H), 3.76–3.70(m, 2H), 2.64 (s, 3H); 13 CNMR (150MHz, D 2 O) δ 174.0, 171.4, 168.1, 166.4, 152.3, 142.0, 103.1, 82.4, 77.9, 73.6, 71.6, 61.4, 55.7, 53.4, 50.2, 33.2; ESI-HRMS: m/ zcalcd for C16H23N5NaO10 [M+Na] + : 468.1337 ; found: 468.1324 .

Claims (10)

1.化合物18,其特征在于:名称为:2’,3’-二-O-苯甲酰基-4’-叠氮基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷,化学结构式为:1. compound 18 is characterized in that: name is: 2',3'-di-O-benzoyl-4'-azido-4'-deoxy-α-D-glucuronic acid methyl ester uridine , the chemical structure is:
Figure FDA0001479137140000011
Figure FDA0001479137140000011
2.权利要求1所述化合物18的制备方法,其特征在于:具体包括如下步骤:2. the preparation method of compound 18 described in claim 1, is characterized in that: specifically comprises the steps: 1)、将2’,3’-二-O-苯甲酰基-4’-叠氮基-4’-去氧-α-D-葡萄糖尿苷,简称为:化合物16,与TEMPO一起加入CH3CN中,再加入醋酸碘苯并反应完全,而后加入无水EtOH进行淬灭反应,浓缩得固体粗品,命名为:化合物17;1), add 2',3'-di-O-benzoyl-4'-azido-4'-deoxy-α-D-glucouridine, referred to as: compound 16, and add CH together with TEMPO 3 CN, then add iodobenzo acetate to complete the reaction, then add anhydrous EtOH to quench the reaction, concentrate to obtain a solid crude product, named: compound 17; 2)、所述化合物17溶于无水CH3OH,加入H2SO4,反应完全,再加入NaHCO3进行淬灭反应,浓缩;用乙酸乙酯萃取反应液,再干燥、过滤、减压浓缩,得化合物18。2), the compound 17 was dissolved in anhydrous CH 3 OH, added H 2 SO 4 , the reaction was complete, then NaHCO 3 was added to quench the reaction, and concentrated; the reaction solution was extracted with ethyl acetate, then dried, filtered, and decompressed. Concentration gave compound 18. 3.根据权利要求2所述的化合物18的制备方法,其特征在于:所述化合物16的合成方法为:将化合物14与尿嘧啶在TMSOTf/BSA/乙腈条件下回流反应得到化合物15,化合物15在Et3N/CH3OH中水解得到化合物16;所述化合物14与15的命名分别为:化合物14:1,6-二-O-乙酰基-2,3-二-O-苯甲酰基-4-叠氮基-4-去氧-α-D-葡萄糖;化合物15:2’,3’-二-O-苯甲酰基-4’-叠氮基-6’-O-乙酰基-4’-去氧-α-D-葡萄糖尿苷。3. the preparation method of compound 18 according to claim 2 is characterized in that: the synthetic method of described compound 16 is: compound 14 and uracil are refluxed under TMSOTf/BSA/acetonitrile conditions to obtain compound 15, compound 15 The compound 16 was obtained by hydrolysis in Et 3 N/CH 3 OH; the names of the compounds 14 and 15 were respectively: compound 14: 1,6-di-O-acetyl-2,3-di-O-benzoyl -4-Azido-4-deoxy-α-D-glucose; Compound 15: 2',3'-Di-O-benzoyl-4'-azido-6'-O-acetyl- 4'-Deoxy-α-D-glucouridine. 4.利用化合物18合成的化合物19,其特征在于:名称为:2’,3’-二-O-苯甲酰基-4’-氨基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷,化学结构式为:4. Compound 19 synthesized by compound 18 is characterized in that: the name is: 2',3'-di-O-benzoyl-4'-amino-4'-deoxy-α-D-glucuronic acid methyl Esteruridine, the chemical structural formula is:
Figure FDA0001479137140000021
Figure FDA0001479137140000021
5.权利要求4所述的化合物19的制备方法,其特征在于:将所述化合物18与SnCl2·H2O、对甲基苯硫酚、CHCl3和Et3N反应,分离获得化合物19。5. The preparation method of compound 19 according to claim 4, characterized in that: the compound 18 is reacted with SnCl 2 ·H 2 O, p-methylthiophenol, CHCl 3 and Et 3 N to separate and obtain compound 19 . 6.利用化合物19合成的化合物20,其特征在于:名称为:(R)-2’,3’-二-O-苯甲酰基-4’-(2”-(2”’-(N-甲基,N-Cbz)氨基)乙酰氨基-3”-羟基)丙酰胺基-4’-去氧-α-D-葡萄糖醛酸甲酯尿苷,化学结构式为:6. Compound 20 synthesized by compound 19 is characterized in that: the name is: (R)-2',3'-di-O-benzoyl-4'-(2"-(2"'-(N- Methyl, N-Cbz) amino) acetamido-3 "-hydroxyl) propionamido-4'-deoxy-α-D-glucuronide methyl uridine, the chemical structural formula is:
Figure FDA0001479137140000022
Figure FDA0001479137140000022
7.权利要求6所述的化合物20的制备方法,其特征在于:以所述化合物19、(R)-2-[2’-(N-甲基,N-Cbz)氨基]乙酰氨基-3-羟基丙酸为原料,以HATU为缩合剂,以2,6-二甲基吡啶为碱,充分反应,经萃取、洗涤、干燥、过滤和浓缩后,分离获得化合物20。7. The preparation method of compound 20 according to claim 6, characterized in that: with the compound 19, (R)-2-[2'-(N-methyl, N-Cbz) amino]acetamido-3 -Hydroxypropionic acid is used as raw material, HATU is used as condensing agent, and 2,6-lutidine is used as base to fully react, and after extraction, washing, drying, filtration and concentration, compound 20 is isolated and obtained. 8.利用化合物20合成的化合物21,其特征在于:名称为:(R)-4’-(2”-(2”’-(N-甲基,N-Cbz)氨基)乙酰氨基-3”-羟基)丙酰胺基-4’-去氧-α-D-葡萄糖醛酸尿苷,化学结构式为:8. Compound 21 synthesized by compound 20 is characterized in that: the name is: (R)-4'-(2"-(2"'-(N-methyl, N-Cbz) amino)acetamido-3" -Hydroxy) propionamido-4'-deoxy-α-D-glucuronide uridine, the chemical structural formula is:
Figure FDA0001479137140000023
Figure FDA0001479137140000023
9.权利要求8所述的化合物21的制备方法,其特征在于:将所述化合物20于0℃下在LiOH的甲醇水溶液中水解,浓缩并进行HPLC制备,得到化合物21。9 . The method for preparing compound 21 according to claim 8 , wherein the compound 21 is obtained by hydrolyzing the compound 20 in LiOH aqueous methanol solution at 0° C., concentrating and performing HPLC preparation. 10 . 10.一种利用权利要求8所述化合物21合成新奥霉素的全合成方法,其特征在于:将所述化合物21和含量为10%的Pd/C加入到EtOH和水中,在氢气的条件下室温反应完全,过滤和浓缩得到新奥霉素。10. a total synthesis method utilizing compound 21 described in claim 8 to synthesize neo-Othomycin, it is characterized in that: described compound 21 and content are that 10% Pd/C is added to EtOH and water, in the condition of hydrogen The reaction was complete at room temperature, filtered and concentrated to obtain neo-Othomycin.
CN201711180837.9A 2017-11-23 2017-11-23 Total synthesis method of neooxytocin Expired - Fee Related CN107973830B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711180837.9A CN107973830B (en) 2017-11-23 2017-11-23 Total synthesis method of neooxytocin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711180837.9A CN107973830B (en) 2017-11-23 2017-11-23 Total synthesis method of neooxytocin

Publications (2)

Publication Number Publication Date
CN107973830A CN107973830A (en) 2018-05-01
CN107973830B true CN107973830B (en) 2020-06-05

Family

ID=62011091

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711180837.9A Expired - Fee Related CN107973830B (en) 2017-11-23 2017-11-23 Total synthesis method of neooxytocin

Country Status (1)

Country Link
CN (1) CN107973830B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109134567B (en) * 2018-07-23 2021-12-24 中国科学院成都生物研究所 Fermentation preparation method of nucleoside antibacterial compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039523A2 (en) * 2001-11-05 2003-05-15 Exiqon A/S OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
CN103965275A (en) * 2014-05-27 2014-08-06 中国科学院成都生物研究所 Separation and extraction method of streptomycete fermentation metabolite xinaomycin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933288B2 (en) * 2002-02-04 2005-08-23 Isis Pharmaceuticals, Inc. Pyranosyl cytosines: pharmaceutical formulations and methods
US20150057243A1 (en) * 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039523A2 (en) * 2001-11-05 2003-05-15 Exiqon A/S OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
CN103965275A (en) * 2014-05-27 2014-08-06 中国科学院成都生物研究所 Separation and extraction method of streptomycete fermentation metabolite xinaomycin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
An Efficient Synthesis of Gougerotin and Related Analogues Using Solid- and Solution-Phase Methodology;Michael T. Migawa,等;《Organic Letters》;20050613;第7卷(第16期);第3430页方案1 *
Nucleosides. LXXV. Synthetic studies on nucleoside antibiotics. 9. Total synthesis of gougerotin;Kyoichi A. Watanabe,等;《Journal of the American Chemical Society》;19720531;第94卷(第9期);第3273页方案1 *

Also Published As

Publication number Publication date
CN107973830A (en) 2018-05-01

Similar Documents

Publication Publication Date Title
CA2598347C (en) Isoxazoline derivative and novel process for its preparation
WO2007082475A1 (en) Novel ent-kaurene diterpene compound and its derivatives, their preparation and their use
CN107973830B (en) Total synthesis method of neooxytocin
CN103275019B (en) The chloro-4-substituted anilinic of 4-[3-]-6-methoxyl group displacement formamido group quinazoline compounds and preparation and application
CN114031623B (en) C 14 Amino-substituted tetrandrine derivative and preparation and application thereof
CN113135840B (en) Synthetic method of conjugated alkenyl amidine compound
CN113234015B (en) 3-acyl dihydroquinoline derivative and preparation method and application thereof
CN104130195B (en) A kind of haptenic synthetic method of carbendazim
CN118598812A (en) Synthesis method of key intermediate of huperzine A
Yamada et al. Total synthesis of the copd biomarker desmosine via stepwise sonogashira cross-coupling reactions
CN110790689B (en) Synthetic method of 1, 1-difluoro-2-isonitrile-ethyl phenyl sulfone compound
CN118026978A (en) Synthesis method of 3-trifluoromethyl chromone compound
CN116217654A (en) Preparation method of linker drug conjugate and intermediate thereof
KR20020016793A (en) 1-Trifluoromethyl-4-Hydroxy-7-Piperidinyl-Aminomethylchroman Derivatives
CN114605437A (en) Synthesis process for preparing three telaprevir medicaments by continuous one-pot method
CN103254143B (en) 4-[4-(2-diethylin kharophen) anilino]-6-substituted quinazoline compounds and Synthesis and applications
WO2016145997A1 (en) Pharmaceutically active sugar molecule and synthesis method thereof
CN113583012B (en) Synthesis method of pyrano [4,3-b ] pyridine-2, 7-dione compound
CN112250639B (en) Heterocyclic substituted arylamine compound and preparation method and application thereof
CN110194760B (en) Method for preparing 3-benzylidene-2-(7'-quinoline)-2,3-dihydro-isoindol-1-one compounds
CN107216360B (en) A method of preparing rope Citropten
CN110003121A (en) A kind of 3,4- dihydroquinazoline derivatives and preparation method thereof, application
CN118440078B (en) Preparation method of biologically active benzoindolizine derivative
CN113214199B (en) A kind of synthetic method of benzofuran-3-oxocarboxylate compound
CN118271227B (en) A method for synthesizing 4-formylpyrrole derivatives by silver catalysis and its application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200605

Termination date: 20211123

CF01 Termination of patent right due to non-payment of annual fee